Trypsin Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Source (Porcine, Bovine, Others), By Application (Biotechnology and Pharmaceutical Industry, Food Industry, Cosmetics and Personal Care, Waste Treatment, Others), By End User (Research, Diagnostics, Industrial use), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 99.76 MIllion
CAGR (2026-2031)	5.87%
Fastest Growing Segment	Bovine
Largest Market	North America
Market Size (2031)	USD 140.47 MIllion

Market Overview

The Global Trypsin Market will grow from USD 99.76 MIllion in 2025 to USD 140.47 MIllion by 2031 at a 5.87% CAGR. Trypsin is a proteolytic enzyme, specifically a serine protease derived primarily from the pancreas of livestock, that functions by hydrolyzing proteins into peptides and amino acids. It serves as a critical reagent in the biopharmaceutical industry for cell dissociation, vaccine manufacturing, and insulin production, while also finding extensive application in the food sector to improve the texture and digestibility of protein-based products. This heavy reliance on life sciences is a primary growth driver; according to the Biotechnology Innovation Organization, in 2024, the revenue for public bioscience companies in the United States grew by 6.8% to reach $205 billion, signaling a robust funding environment that directly supports the consumption of essential bioprocessing tools like trypsin.

Despite this upward trajectory, the market faces a significant challenge regarding the sourcing of raw materials. The dependence on animal-derived extraction exposes the supply chain to risks associated with livestock diseases and viral contamination, prompting stringent regulatory scrutiny. These safety concerns necessitate rigorous and costly purification processes to meet pharmaceutical standards. Consequently, the volatility of animal sourcing and the complexity of ensuring pathogen-free products create substantial bottlenecks that can impede the scalability and broader commercial expansion of trypsin products globally.

Key Market Drivers

The Expansion of the Biopharmaceutical Industry and Vaccine Production acts as a primary catalyst for the Global Trypsin Market, driven by the enzyme's indispensable function in cell culture workflows. Trypsin is the standard proteolytic agent used for harvesting adherent cells and dissociating tissues, a fundamental step in producing viral vectors and vaccines. As pharmaceutical giants scale their manufacturing capabilities to combat infectious diseases, the consumption of high-grade trypsin for upstream bioprocessing has surged. This trend is exemplified by major infrastructure investments aimed at boosting local production capacities. For instance, according to Sanofi, May 2024, in the 'Sanofi opens new advanced vaccines facility' press release, the company invested approximately $586 million to inaugurate a state-of-the-art vaccine manufacturing site in Toronto, directly increasing the operational demand for essential bioprocessing reagents.

The Critical Role in Commercial Insulin Manufacturing Processes further propels growth, as trypsin is required to enzymatically cleave proinsulin into the active insulin hormone. This application is vital for meeting the escalating global need for diabetes management therapies. According to the World Health Organization, in 2024, the number of adults living with diabetes worldwide surpassed 800 million, creating an urgent pressure on supply chains to enhance therapeutic output. Leading manufacturers are responding by rapidly expanding infrastructure to ensure adequate supply. According to Novo Nordisk, June 2024, in the 'Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity' press release, the company committed $4.1 billion to build a second fill and finishing facility, underscoring the aggressive scaling of insulin-related operations that rely on trypsin.

Download Free Sample Report

Key Market Challenges

The reliance on animal-derived extraction represents a formidable barrier to the scalability of the Global Trypsin Market. Since trypsin is predominantly sourced from the pancreas of livestock, specifically pigs and cattle, the supply chain is inherently vulnerable to biological risks and volatility within the agricultural sector. This dependence exposes manufacturers to sudden disruptions caused by epizootic outbreaks, which not only constrain the volume of available raw materials but also trigger stringent regulatory embargoes on animal by-products from affected regions.

These biological threats directly translate into market instability. According to the World Organisation for Animal Health, in 2024, the persistent spread of African Swine Fever affected domestic swine populations in over 60 countries, significantly restricting the trade and availability of porcine-derived materials essential for trypsin extraction. Such widespread disease prevalence forces manufacturers to navigate complex safety protocols to ensure pathogen-free ingredients. The resulting necessity for rigorous viral inactivation and purification processes escalates production costs and extends lead times, creating a substantial bottleneck that impedes the industry’s ability to efficiently meet the rising demand from the biopharmaceutical sector.

Key Market Trends

Integration into automated high-throughput proteomics workflows is fundamentally reshaping the Global Trypsin Market, as research institutions demand enzyme solutions that offer exceptional consistency for large-scale sample preparation. Modern analytical platforms require highly active and stable trypsin to ensure complete and reproducible protein digestion within reduced timeframes, a requirement that is critical for population-scale health studies. This trend toward massive, streamlined processing is driving the consumption of specialized reagent grades capable of supporting continuous operation without variability. According to Thermo Fisher Scientific, January 2025, in the 'Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study' press release, the UK Biobank Pharma Proteomics Project selected the company’s platform to analyze over 5,400 proteins across approximately 600,000 samples, a scale that directly underscores the escalating volume of enzymatic reagents needed for high-throughput biological investigation.

The increasing application in cultivated meat and cellular agriculture represents a burgeoning frontier for trypsin consumption, where the enzyme is utilized as a vital dissociation agent for harvesting biomass and maintaining cell viability during expansion. As this emerging industry transitions from pilot-scale research to commercial manufacturing, substantial investment is being directed toward optimizing bioprocesses and securing the supply chain for essential inputs. This focus on scaling production capabilities is vital for making cell-based protein products commercially viable and accessible. According to The Good Food Institute, March 2025, in the '2024 State of the Industry: Cultivated meat, seafood, and ingredients' report, the sector demonstrated its resilience and focus on industrialization with Prolific Machines securing a $54.6 million Series B funding round, an investment specifically aimed at advancing the biomanufacturing technologies that rely on such critical cell culture components.

Segmental Insights

Based on recent market intelligence, the Bovine segment is identified as the fastest-growing category within the Global Trypsin Market. This rapid expansion is primarily driven by the booming biopharmaceutical industry, where bovine-derived trypsin is the preferred choice for critical applications such as cell culture, vaccine manufacturing, and insulin production. Industry analysis indicates that the segment's growth is fueled by the enzyme's high specificity, superior stability, and cost-effectiveness in large-scale biologic processing compared to alternatives. Furthermore, the established regulatory frameworks ensuring the purity of bovine sources support their accelerated adoption in developing therapeutic proteins and monoclonal antibodies globally.

Regional Insights

North America maintains a leading position in the global trypsin market, driven primarily by its extensive pharmaceutical and biotechnology sectors. The region experiences high demand for trypsin due to widespread application in cell culture, insulin production, and vaccine development. This dominance is supported by significant investment in life sciences research and the presence of key industry manufacturers. Additionally, stringent quality standards enforced by the U.S. Food and Drug Administration regarding biopharmaceutical manufacturing ensure the consistent utilization of high-grade enzymes, effectively sustaining the region’s market superiority.

Recent Developments

• In October 2024, Novo Nordisk Pharmatech launched TrypsiNNex, a new recombinant, animal-free trypsin product designed specifically for the pharmaceutical manufacturing sector. This strategic addition to the company's portfolio aimed to address the critical industry need for sustainable and high-quality raw materials in bioprocessing applications, such as cell dissociation and insulin production. By eliminating animal-derived components, the product was engineered to reduce contamination risks and ensure low batch-to-batch variability, thereby enhancing the safety and consistency of final drug products. The release underscored the company's commitment to supporting the Global Trypsin Market with reliable, excipient-GMP level enzymes.
• In April 2024, Thermo Fisher Scientific released a new line of high-purity, animal-free recombinant trypsin solutions engineered for large-scale biomanufacturing facilities. This development was intended to improve the efficiency and safety of biopharmaceutical production processes by providing consistent, contaminant-free enzyme options that meet stringent regulatory standards. The launch reflected the company's response to the evolving demands of the Global Trypsin Market for more sustainable and dependable bioprocessing tools. These advanced formulations were designed to support the industry's shift away from animal-derived reagents, significantly reducing potential viral contamination risks in cell culture and vaccine manufacturing.
• In February 2024, Novozymes and Chr. Hansen finalized their merger to form Novonesis, a new global biosolutions entity with significant influence in the enzyme industry. This strategic combination united two leading companies with extensive capabilities in microbial and enzymatic technologies, including the production of trypsin for various industrial and pharmaceutical applications. The merger created a powerhouse with a vast network of research and development centers, aiming to drive innovation and sustainability across the biosolutions sector. This consolidation represented a major structural change impacting the competitive landscape of the Global Trypsin Market by integrating complementary bio-industrial strengths.
• In January 2024, Creative Enzymes introduced a new enzymatic innovation comprising a potent combination of Trypsin and Chymotrypsin. This product launch was positioned as a significant advancement aimed at enhancing operational efficiencies across various industrial applications within the Global Trypsin Market. The proteolytic enzyme blend was developed to leverage the synergistic effects of the two proteases, offering substantial improvements for sectors such as pharmaceuticals and biotechnology. The company highlighted that this release represented a notable milestone in its efforts to provide high-quality enzyme-related products that address complex challenges in protein digestion and sequence analysis.

Key Market Players

• Merck KGaA
• Novozymes A/S, part of Novonesis Group
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc
• Sartorius AG
• Bioseutica BV
• Biozym Scientific GmbH
• PromoCell GmbH
• Promega Corporation
• Bovogen Biologicals Pty Ltd

By Source	By Application	By End User	By Region
Porcine Bovine Others	Biotechnology and Pharmaceutical Industry Food Industry Cosmetics and Personal Care Waste Treatment Others	Research Diagnostics Industrial use	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Trypsin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Trypsin Market , By Source:

• Porcine
• Bovine
• Others

• Trypsin Market , By Application:

• Biotechnology and Pharmaceutical Industry
• Food Industry
• Cosmetics and Personal Care
• Waste Treatment
• Others

• Trypsin Market , By End User:

• Research
• Diagnostics
• Industrial use

• Trypsin Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE